Nuedexta

RSS

Withdrawn

This medicine's authorisation has been withdrawn

dextromethorphan hydrobromide / quinidine sulfate
MedicineHumanWithdrawn

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 15 February 2016 the European Commission withdrew the marketing authorisation for Nuedexta (dextromethorphan / quinidine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Jenson Pharmaceutical Services Ltd, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Nuedexta was granted marketing authorisation in the EU on 24 June 2013 for treatment of pseudobulbar affect (PBA) in adults. The product had not been marketed in the EU. 

The European Public Assessment Report (EPAR) for Nuedexta is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (312.89 KB - PDF)

Vaata

español (ES) (266.25 KB - PDF)

Vaata

čeština (CS) (293.48 KB - PDF)

Vaata

dansk (DA) (266.6 KB - PDF)

Vaata

Deutsch (DE) (267.83 KB - PDF)

Vaata

eesti (ET) (269.56 KB - PDF)

Vaata

ελληνικά (EL) (320.31 KB - PDF)

Vaata

français (FR) (267.84 KB - PDF)

Vaata

hrvatski (HR) (283.73 KB - PDF)

Vaata

italiano (IT) (264.25 KB - PDF)

Vaata

latviešu (LV) (302.74 KB - PDF)

Vaata

lietuvių (LT) (283 KB - PDF)

Vaata

magyar (HU) (284.97 KB - PDF)

Vaata

Malti (MT) (290.76 KB - PDF)

Vaata

Nederlands (NL) (264.69 KB - PDF)

Vaata

polski (PL) (284.4 KB - PDF)

Vaata

português (PT) (286.28 KB - PDF)

Vaata

română (RO) (268.86 KB - PDF)

Vaata

slovenčina (SK) (285.42 KB - PDF)

Vaata

slovenščina (SL) (286.75 KB - PDF)

Vaata

suomi (FI) (262.95 KB - PDF)

Vaata

svenska (SV) (265.02 KB - PDF)

Vaata

Product information

български (BG) (1.24 MB - PDF)

Vaata

español (ES) (638.47 KB - PDF)

Vaata

čeština (CS) (994 KB - PDF)

Vaata

dansk (DA) (630.24 KB - PDF)

Vaata

Deutsch (DE) (690.2 KB - PDF)

Vaata

eesti (ET) (627.09 KB - PDF)

Vaata

ελληνικά (EL) (1.36 MB - PDF)

Vaata

français (FR) (691.37 KB - PDF)

Vaata

hrvatski (HR) (642.16 KB - PDF)

Vaata

italiano (IT) (651.76 KB - PDF)

Vaata

latviešu (LV) (994.32 KB - PDF)

Vaata

lietuvių (LT) (810.7 KB - PDF)

Vaata

magyar (HU) (994.57 KB - PDF)

Vaata

Malti (MT) (1.04 MB - PDF)

Vaata

Nederlands (NL) (663.87 KB - PDF)

Vaata

polski (PL) (1.71 MB - PDF)

Vaata

português (PT) (649.06 KB - PDF)

Vaata

română (RO) (655.52 KB - PDF)

Vaata

slovenčina (SK) (976.88 KB - PDF)

Vaata

slovenščina (SL) (925.24 KB - PDF)

Vaata

suomi (FI) (653.71 KB - PDF)

Vaata

svenska (SV) (642.3 KB - PDF)

Vaata

Íslenska (IS) (955.72 KB - PDF)

Vaata

norsk (NO) (943.33 KB - PDF)

Vaata
Latest procedure affecting product information:IAIN/0005
24/10/2014
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (167.05 KB - PDF)

Vaata

español (ES) (153.71 KB - PDF)

Vaata

čeština (CS) (160.1 KB - PDF)

Vaata

dansk (DA) (154.47 KB - PDF)

Vaata

Deutsch (DE) (154.57 KB - PDF)

Vaata

eesti (ET) (153.66 KB - PDF)

Vaata

ελληνικά (EL) (177.22 KB - PDF)

Vaata

français (FR) (153.69 KB - PDF)

Vaata

hrvatski (HR) (282.98 KB - PDF)

Vaata

italiano (IT) (152.66 KB - PDF)

Vaata

latviešu (LV) (164.45 KB - PDF)

Vaata

lietuvių (LT) (154.89 KB - PDF)

Vaata

magyar (HU) (160.64 KB - PDF)

Vaata

Malti (MT) (160.78 KB - PDF)

Vaata

Nederlands (NL) (153.75 KB - PDF)

Vaata

polski (PL) (159.71 KB - PDF)

Vaata

português (PT) (154.08 KB - PDF)

Vaata

română (RO) (153.69 KB - PDF)

Vaata

slovenčina (SK) (159.39 KB - PDF)

Vaata

slovenščina (SL) (157.93 KB - PDF)

Vaata

suomi (FI) (152.94 KB - PDF)

Vaata

svenska (SV) (136.89 KB - PDF)

Vaata

Íslenska (IS) (169.64 KB - PDF)

Vaata

norsk (NO) (170.1 KB - PDF)

Vaata

Product details

Name of medicine
Nuedexta
Active substance
  • dextromethorphan
  • quinidine
International non-proprietary name (INN) or common name
  • dextromethorphan hydrobromide
  • quinidine sulfate
Therapeutic area (MeSH)
Neurobehavioral Manifestations
Anatomical therapeutic chemical (ATC) code
N07XX59

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.

Authorisation details

EMA product number
EMEA/H/C/002560
Marketing authorisation holder
Jenson Pharmaceutical Services Limited

Carradine House
237 Regents Park Road
London
N3 3LF
United Kingdom

Marketing authorisation issued
24/06/2013
Withdrawal of marketing authorisation
15/02/2016
Revision
2

Assessment history

This page was last updated on

Share this page